Genomic characterization of New Delhi metallo‐beta‐lactamase–producing species of Morganellaceae, Yersiniaceae, and Enterobacteriaceae (other than Klebsiella) from Brazil over 2013–2022

Abstract

Over the last decade, New Delhi metallo‐beta‐lactamase (NDM) carbapenemase has silently spread in Brazil. In this study, we analyzed a large collection of Enterobacterales other than Klebsiella spp. received in our reference laboratory between 2013 and 2022. A total of 32 clinical isolates displaying different pulsed‐field gel electrophoresis profiles, and represented by 11 species in the families Enterobacteriaceae (Citrobacter freundii, Citrobacter portucalensis, Enterobacter hormaechei, and Escherichia coli), Morganellaceae (Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, and Raoultella ornithinolytica), and Yersiniaceae (Serratia marcescens) had their whole genomes sequenced and further analyzed. Antimicrobial susceptibility was determined by disk diffusion, except for polymyxin B, assessed by broth microdilution. The blaNDM‐1 allele was predominant (n = 29), but blaNDM‐5 was identified in an E. coli specimen with a novel ST, and the blaNDM‐7 allele was found in E. hormaechei ST45 and E. coli ST1049. Polymyxin was active against all but one Enterobacteriaceae isolate: an mcr‐1–producing E. coli presenting minimal inhibitory concentration (4 mg/L). Isolates producing extended‐spectrum β‐lactamases were common: cefotaximase from Munich (CTX‐M)‐15 (n = 10), CTX‐M‐2 (n = 4), and CTX‐M‐8 (n = 3) were detected, and the mcr‐1–producing E. coli was found to co‐produce both CTX‐M‐8 and CTX‐M‐55 β‐lactamases. The mcr‐9 gene was found in 5/8 E. hormaechei isolates, distributed in four different sequence types, all of them presenting susceptibility to polymyxin. This study showed that NDM‐producing Enterobacterales other than Klebsiella are already spread in Brazil, in diversified species, and cocarrying important resistance genes. Prompt detection and effective implementation of measures to prevent further spread are mandatory for mitigating the dissemination of NDM carbapenemase in hospital settings and preserving the already limited antimicrobial therapy options.